Stifel Downgrades Sage Therapeutics to Hold, Lowers Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Paul Matteis has downgraded Sage Therapeutics from Buy to Hold and lowered the price target from $60 to $22.
August 07, 2023 | 3:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has been downgraded from Buy to Hold by Stifel, with a lowered price target from $60 to $22.
The downgrade from Buy to Hold by Stifel indicates a less optimistic outlook for the company. The significant reduction in the price target from $60 to $22 suggests that the analyst sees less upside potential in the stock, which could negatively impact investor sentiment and put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100